Abstract:Abstract Objective Stage I‐II uterine papillary serous carcinoma (UPSC) has aggressive biological behavior and leads to poor prognosis. However, clinicopathologic risk factors to predict cancer‐specific survival of patients with stage I‐II UPSC were still unclear. This study was undertaken to develop a prediction model of survival in patients with early‐stage UPSC. Methods Using Surveillance, Epidemiology, and End Results (SEER) database, 964 patients were identified with International Federation of Gynecology and Obstetrics (FIGO) stage I‐II UPSC who underwent at least hysterectomy between 2004 and 2015. By considering competing risk events for survival outcomes, we used proportional subdistribution hazards regression to compare cancer‐specific death (CSD) for all patients. Based on the results of univariate and multivariate analysis, the variables were selected to construct a predictive model; and the prediction results of the model were visualized using a nomogram to predict the cancer‐specific survival and the response to adjuvant chemotherapy and radiotherapy of stage I‐II UPSC patients. Results The median age of the cohort was 67 years. One hundred and sixty five patients (17.1%) died of UPSC (CSD), while 8.6% of the patients died from other causes (non‐CSD). On multivariate analysis, age ≥ 67 (HR = 1.45, P = .021), tumor size ≥ 2 cm (HR = 1.81, P = .014) and >10 regional nodes removed (HR = 0.52, P = .002) were significantly associated with cumulative incidence of CSD. In the age ≥67 cohort, FIGO stage IB‐II was a risk factor for CSD (HR = 1.83, P = .036), and >10 lymph nodes removed was a protective factor (HR = 0.50, P = .01). Both adjuvant chemotherapy combined with radiotherapy and adjuvant chemotherapy alone decreased CSD of patients with stage I‐II UPSC older than 67 years (HR = 0.47, P = .022; HR = 0.52, P = .024, respectively). The prediction model had great risk stratification ability as the high‐risk group had higher cumulative incidence of CSD than the low‐risk group (P < .001). In the high‐risk group, patients with post‐operative adjuvant chemoradiotherapy had improved CSD compared with patients who did not receive radiotherapy nor chemotherapy (P = .037). However, there was no such benefit in the low‐risk group. Conclusion Our prediction model of CSD based on proportional subdistribution hazards regression showed a good performance in predicting the cancer‐specific survival of early‐stage UPSC patients and contributed to guide clinical treatment decision, helping oncologists and patients with early‐stage UPSC to decide whether to choose adjuvant therapy or not.

TXNDC17 Protein Overexpression in Uterine Papillary Serous Carcinoma is Associated with Chemoresistance

TXNDC17 Protein Overexpression in Uterine Papillary Serous Carcinoma is Associated with Clinicopathological Characteristics and Prognosis

TXNDC17 Promotes Paclitaxel Resistance Via Inducing Autophagy in Ovarian Cancer

Ccdc170 Affects Breast Cancer Apoptosis Through Ire1 Pathway

Down-regulation of UTP23 Promotes Paclitaxel Resistance and Predicts Poorer Prognosis in Ovarian Cancer.

Clinicopathological Characteristics and Her-2/neu Status in Chinese Patients with Uterine Papillary Serous Carcinoma

[Clinical Significance of Her-2/neu Status in Patients with Uterine Papillary Serous Carcinoma].

[Clinicopathologic study on 61 cases of uterine papillary serous carcinoma with or without adjuvant therapy]

Is Overexpression of Ki-67 a Prognostic Biomarker of Upper Tract Urinary Carcinoma? A Retrospective Cohort Study and Meta-Analysis

High TXNDC5 Expression Predicts Poor Prognosis in Renal Cell Carcinoma

High TPX2 expression results in poor prognosis, and Sp1 mediates the coupling of the CX3CR1/CXCL10 chemokine pathway to the PI3K/Akt pathway through targeted inhibition of TPX2 in endometrial cancer

A Novel Model to Predict Cancer-Specific Survival in Patients with Early-Stage Uterine Papillary Serous Carcinoma (UPSC).

Neoantigens and the tumor microenvironment play important roles in the prognosis of high-grade serous ovarian cancer

Increased Expression of SOX2 Predicts A Poor Prognosis and Promotes Malignant Phenotypes in Upper Tract Urothelial Carcinoma

[Clinical and Pathologic Analysis of 33 Cases of Uterine Papillary Serous Carcinoma].

TPD52 as a Potential Prognostic Biomarker and its Correlation with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma: Bioinformatic Analysis and Experimental Verification

Prognostic Significance of PD-L1 Expression on Tumor Cells and Tumor-Infiltrating Mononuclear Cells in Upper Tract Urothelial Carcinoma

Prognostic value of HER2 expression levels for upper tract urothelial carcinoma.

Comprehensive Analysis of Ubiquitin-Proteasome System Genes Related to Prognosis and Immunosuppression in Head and Neck Squamous Cell Carcinoma

The Expression and Clinical Significance of PD-L1 in Patients with Upper Tract Urothelial Carcinoma.

Overexpression of TICRR and PPIF confer poor prognosis in endometrial cancer identified by gene co-expression network analysis